AdvaMed® Comment Letter to OIG – January 27, 2023
AdvaMed® responded to HHS OIG’s annual solicitation of proposals for new and modified safe harbors and special fraud alerts.
Letter to the Editor: Article on Device Sterilization Didn’t Provide the Complete Picture
Lucy Fraiser, Ph.D., a board-certified toxicologist, recently responded in a letter to the editor of Modern Healthcare about the publication’s recent coverage of the EPA’s work on ethylene oxide.
AdvaMed® Submits Comments on CY 2023 OPPS/ASC Proposed Rule
AdvaMed® submitted comments to CMS on the CY 2023 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule.
AdvaMed® Submits Comments on the CY 2023 PFS Proposed Rule
AdvaMed® submitted comments to CMS on the Calendar Year 2023 Physician Fee Schedule (PFS) proposed rule.
AdvaMed® Responds to CMS’ Request for Information Regarding Medicare Advantage
AdvaMed® submitted a letter to CMS’s RFI on Medicare regarding ways to strengthen the Medicare Advantage program to align with the Vision for Medicare and CMS’ Strategic Pillars.
AdvaMed® Submits Comments on CY 2023 ESRD PPS Proposed Rule
AdvaMed® submitted comments to CMS the CY 2023 End Stage Renal Disease (ESRD) Prospective Payment System.
AdvaMed® Submits Comments on Genetic Testing in Oncology LCD
AdvaMed® submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.
AdvaMed® Submits Comments on FY 2023 IPPS Proposed Rule
AdvaMed® submitted comments to CMS on the Fiscal Year 2023 Hospital Inpatient Prospective Payment System proposed rule.
AdvaMed® Comments on Proposed Delay of Radiation Oncology Model
AdvaMed® submitted comments to the Center for Medicare and Medicaid Services (CMS) on its Radiation Oncology (RO) Model proposed rule proposing to indefinitely delay the start date of the RO…
AdvaMed® Submits Comments on Local Coverage Determination of Skin Substitutes
AdvaMed® submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”